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E-mail address: xlyang@scripps.edu (X.-L. Yang).Known as an essential component of the translational apparatus, the aminoacyl-tRNA synthetase
family catalyzes the ﬁrst step reaction in protein synthesis, that is, to speciﬁcally attach each amino
acid to its cognate tRNA. While preserving this essential role, tRNA synthetases developed other
roles during evolution. Human tRNA synthetases, in particular, have diverse functions in different
pathways involving angiogenesis, inﬂammation and apoptosis. The functional diversity is further
illustrated in the association with various diseases through genetic mutations that do not affect
aminoacylation or protein synthesis. Here we review the accumulated knowledge on how human
tRNA synthetases used structural inventions to achieve functional expansions.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
When sequencing of the human genome was completed in
2004, it was a surprise to many of us that the number of protein-
coding genes in human was not much more than that in the simple
roundworm Caenorhabditis elegans [1,2]. The shock was followed
by the realization that the complexity of higher organisms is not
necessarily reﬂected by a larger number of protein-coding genes
[3]. We now understand that alternative splicing occurs on a wide
scale, so that one gene can give rise to many different gene prod-
ucts [4]. In addition, individual proteins have expanded uses, and
are regulated at multiple levels to support and to integrate diverse
biological systems in humans.
Because of their essential role in protein synthesis, genes encod-
ing aminoacyl-tRNA synthetases (AARS) appeared at the onset of
evolution of life. As a family of 20 enzymes in general (one for each
amino acid), AARSs activate amino acids for protein synthesis,
through speciﬁc ligation of each amino acid to its cognate tRNA.
While constrained by evolutionary pressure to preserve this essen-chemical Societies. Published by E
AP II, endothelial monocyte-
-activated inhibitor of trans-
r 1 (containing a, b, c, d
ataxia telangiectasia mutated
, interferon-inducible protein
dherin, vascular endothelialtial activity, AARSs still managed to develop additional functions
during evolution (reviewed in [5–8]). Interestingly, in higher
eukaryotic cells, AARSs are organized into a high molecular mass
multisynthetase complex (MSC), where nine AARSs and three
accessory proteins are bound together [9]. This complex may pro-
mote a more organized protein synthesis and is also thought to
serve as a reservoir of regulation molecules for functions beyond
aminoacylation [10,11]. (Expanded functions and higher-order
interactions of human AARSs are summarized in Table 1.)
While early work in bacteria and lower eukaryotes pointed to
alternative functions for some AARSs [12–14], a rich and diverse
set of expanded functions was found in higher eukaryotes, espe-
cially in human tRNA synthetases. Some of these expanded func-
tions were inferred by connections, including causal associations,
of speciﬁc diseases with tRNA synthetases [8,15]. Others were
demonstrated by direct experiments showing a role in pathways
ranging from inﬂammation, angiogenesis, angiostasis, apoptosis
and autoimmunity. Adding further weight to the concept of ex-
panded functions was the discovery of mutations in genes for tRNA
synthetases that are causally linked to disease and, at the same
time, do not affect aminoacylation activity or protein synthesis
[16–18]. Thus, the concept of alternative functions for tRNA syn-
thetases is now well established.
However, the understanding of how these alternative functions
were developed is at its infancy. This understanding has to accom-
modate the observation that, throughout evolution, the 20 synthe-
tases were constructed on the foundation of one of two basic
architectures, which are referred to as class I or class II. The 10 classlsevier B.V. All rights reserved.
Table 1
Mechanism of expanded function and higher-order interactions of human aminoacyl-tRNA synthetases and their associated factors.
AspRS Component of MSC via interaction with MSC p38 [79]
Nonspeciﬁc tRNA binding using the appended N-terminal helix [34,38,39]
Charged tRNA transfer to eEF-1a facilitated by the N-helix [26]
LysRS Component of MSC via p38 interaction using adapted core enzyme [79,92]
Transcription activation of MITF and USF2 via direct interaction [107,111]
Interaction with Gag through homodimer interface for tRNALys incorporation into HIV [100,101]
Proinﬂammatory response [112]
AsnRS Autoimmune response via interaction with chemokine receptor CCR3 [113]
Anti-apoptosis [114]
ArgRS Component of MSC via interaction using appended leucine-zipper [10,30,79]
Providing Arg-tRNAArg for posttranslational arginylation [82,115,116]
ValRS Complex with eEF-1H using the appended GST domain [28,29,73]
CysRS Complex with eEF-1c using the appended GST domain [74]
Association with diabetic nephropathy [117]
MetRS Component of MSC via interaction using appended GST domain [30,31]
rRNA transcription [118]
GluProRS Component of MSC via interaction using appended WHEP domains [59,83,106]
Transcription repression by forming WHEP domain-dependent GAIT complex [68,69]
GlyRS Causal link to neuropathy via mutations may or may not affect aminoacylation [16,119–122]
Autoimmune response [123]
HisRS Autoimmune response provoked by the appended WHEP domain [124]
TrpRS Angiostasis by inhibiting VE-cadherin using the active site [96,98,105]
TyrRS (mini-TyrRS) Angiogenesis through ELR motif invention on the catalytic domain [55,87,88]
(C-TyrRS) EMAP II-like cytokine [125]
Causal link to neuropathy via mutations may or may not affect aminoacylation [126]
SerRS Vascular development [127,128]
ThrRS Autoimmune response [129]
PheRS Erythroleukemia cell differentiation [130]
LeuRS Component of MSC via interaction using appended domain [84]
Complex with eEF-1c [27]
GlnRS Component of MSC via interaction using adapted catalytic domain [93]
Anti-apoptosis via interaction with ASK1 [131]
IleRS Component of MSC via interaction using appended domain [30,59]
Autoimmune response [129]
AlaRS Autoimmune response [132]
MSC p43 Proliferation, angiostasis, and pro-apoptosis (leucine-zipper containing N-half) [133–135]
Angiostasis via interactions with ATP synthase, integrin a5b1 and PSMA7 (EMAP II) [136,137]
Glucagon-like hormone [138]
Autoimmune regulation by retrieving gp96 in endoplasmic reticulum [139]
Axonal development via interaction with neuroﬁlament light subunit [140]
TGF-b down-regulation via interaction with Smurf2 [141]
MSC p38 Regulate lung cell differentiation via FBP interaction and degradation [142]
Involved in neurodegeneration as a substrate of parkin [143]
Pro-apoptosis via interaction with p53 to prevent its degradation [144]
MSC p18 Tumor suppressor via interaction with ATM and ATR [72,75]
M. Guo et al. / FEBS Letters 584 (2010) 434–442 435I enzymes have a catalytic domain based on a Rossmann nucleotide
binding fold, while the catalytic domain of the 10 class II enzymes
is a 7-stranded b-sheet with ﬂanking a-helices [19]. These two
architectures appeared at the base of the tree of life and, with rare
exception [20], the class to which a synthetase is assigned is ﬁxed
throughout evolution. Thus, expanded functions for each synthe-
tase were developed in the context of a ﬁxed architecture for the
catalytic unit, and functional expansion took place without dis-
turbing the essential catalytic activity.
As described here, nature used structural inventions that, as
higher organisms appeared, built upon and expanded the sizes of
tRNA synthetases, and also invaded the catalytic unit itself to make
subtle changes that did not perturb the canonical aminoacylation
activity. In addition, inventions were made to regulate the elucida-
tion of alternative activities, and even to switch the activity of a
synthetase from a ‘pure’ aminoacylation function to an alternative
function in cell signaling pathways.
2. Functional expansion through acquisition of extra domains
The fusion of a new domain to an existing protein is a straight-
forward way to introduce a new function. Indeed, compared with
their prokaryotic or lower eukaryotic counterparts, all human
AARS (except for AlaRS) have extra domains or motifs at eitherthe N- or C-terminus [5,21,22] (Fig. 1). Although some of those do-
mains are thought to promote tRNA interactions [23,24] or to facil-
itate product transfer to the elongation factor [25–29], these
domains in most cases are dispensable for aminoacylation. For
those AARSs that are components of the MSC, the appended do-
mains are involved in the formation of the complex [30,31]. Sup-
porting this idea, some of the appended domains needed for MSC
formation emerged concurrently with the appearance of the MSC
in Drosophila [32]. However, about half of the 20 synthetases are
not components of the MSC, and yet the frequency of appearance
of appended domains in those free tRNA synthetases is similar to
that of the bound members of the MSC. Thus, while the need for
appended domains to form the MSC seems clear, the appended do-
mains in non-MSC enzymes suggest that other interactions also oc-
cur. Indeed, the interactions of the appended domains with
partners, such as cell surface receptors, cytoplasmic and nuclear
proteins, or nucleic acids, facilitate new functions.
2.1. N-terminal amphiphilic helix – a motif originated from tRNA
binding
An N-terminal extension that is absent in their prokaryotic
orthologs is found in human LysRS, AspRS and AsnRS. These three
class II synthetases are more closely related to each other than to
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Fig. 1. Appended domain/motifs in human AARSs and MSC-associated factors. Except for human AlaRS, all AARSs have appended domains compared to their bacterial or
archaeal homologues. The conserved catalytic domains and tRNA recognition domains are shown as white and gray boxes. N-terminal single helices are present in three class
IIb AARSs. Homologous GST domains are shown in the N-terminal regions of MetRS, GluProRS, ValRS and CysRS, as well as in the C-terminal regions of MSC p18 and p38. MSC
p38 also contains a leucine zipper motif (LZ) and is involved in interactions with leucine-zippers of MSC p43 and ArgRS. The EMAPII domains in MSC p43 and TyrRS are
related. Homologous WHEP domains are shared by ﬁve human AARSs. Many other appended domains in AARSs are idiosyncratic to each enzyme and remain to be further
characterized. Many AARSs and their associated factors (i.e. GluProRS, MetRS, CysRS, MSC p38 and p43) contain more than one type of appended domain.
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separate subclass designated as IIb [33] (Fig. 1). According to sec-
ondary structure predictions, each N-extension contains a helix
of variable length ranging from 20 to 40 amino acids. A NMR struc-
ture determination of the N-terminal extension of human AspRS
conﬁrmed it has a helical conformation [34]. Those helices, in gen-
eral, are amphiphilic with charged residues on one side, and hydro-
phobic residues on the other (Fig. 2).
The hydrophilic side of the N-terminal helix of human LysRS is
dominated by positively charged residues – ideal for binding neg-
atively charged nucleic acids (Fig. 2). Indeed, the N-terminal exten-
sion of human LysRS binds to the TwC stem–loop region of tRNALys
and thereby increases the afﬁnity of the synthetase for its tRNA
[24,35]. The role of LysRS in HIV packaging depends on the N-ter-
minal extension, presumably because of its tRNA interaction [36]
(Table 1). In this role, LysRS interacts with tRNALys3 to deliver it
to the virion to function as a primer for reverse transcription [37].
Similar to human LysRS, the amphiphilic N-terminal helices of
yeast AspRS and of yeast AsnRS are also positively charged, with
tRNA binding properties demonstrated for the N-extension of
AspRS [38]. When appended to a catalytic domain, these N-termi-
nal helices can enhance tRNA binding afﬁnities of the extended
tRNA synthetases [23,35,39,40].
However, because of the non-speciﬁc nature of electrostatic
interactions, these helices unsurprisingly bind to different tRNAs
and to different sites on tRNA [24,38]. Furthermore, similar helical
motifs occur in a series of double-stranded RNA-recognizing pro-
teins [41,42], suggesting that the N-terminal helix motif may be
used broadly to function in associating with other types of RNA
in the cellular environment.
Interestingly, compared to the yeast enzymes, human AspRS
has more of the negatively charged residues located in the N-ter-
minal helix (Fig. 2). Thus, the amphiphilic helices may have
evolved from facilitating tRNA binding to facilitating other interac-
tions in higher eukaryotes [43]. This paradigm, of starting in lower
organisms with an appended domain that has nucleic acid binding
properties and evolving towards another function in higher organ-
isms, is seen in other examples, such as the EMAP II domain.2.2. EMAP II domain – a second motif originated from tRNA binding
The C-terminal portion of human TyrRS contains an extra do-
main that is absent in its yeast ortholog (Fig. 1). This domain is
highly homologous to a known cytokine – endothelial monocyte-
activating polypeptide II (EMAP II) [44], which is a C-terminal pro-
teolytic fragment of a component of the MSC known as p43 [45]
(Fig. 1). The EMAP II domain is homologous to the homodimeric
tRNA binding protein Trbp111 [46]. The crystal structures of EMAP
II and the C-domain of human TyrRS were solved [47–49], and the
highly homologous structures were seen to each contain an oligo-
nucleotide-binding (OB) fold b-barrel, while EMAP II and C-TyrRS
have an additional motif that mimics the dimer interface in
Trbp111 [48] (Fig. 2). As a result of the internal dimer-like interface,
the EMAP II domains aremonomers [48]. Interestingly, EMAP II-like
domains are found only in tRNA synthetases, including those ap-
pended to the C-terminus of nematode and plant MetRS, or in tRNA
synthetase-associated proteins, including p43 and yeast Arc1p [50].
(In yeast, there is a smaller synthetase complex formed by MetRS,
GluRS and a non-catalytic protein called Arc1p [51].) As a trans-act-
ing factor, the EMAP II domain in Arc1p enhances catalytic activities
of the associated tRNA synthetases and maintains their cytosolic
localization [52,53]. Same functions could be achieved in cis, when
the EMAP II domain was directly grafted into the catalytic core of
MetRS [54]. Although retaining some of the tRNA binding proper-
ties of Trbp111 [50], the EMAP II domain in human TyrRS is dispens-
able for aminoacylation [55]. Similarly, the association of MSC p43
with human ArgRS does not improve the tRNA aminoacylation
properties [56]. Instead, the EMAP II domains are associated with
cytokine activities (Table 1) and are bound to speciﬁc receptors
[57,58]. Thus, while the EMAP II domains may have originally
developed for RNA binding, throughout evolution, they apparently
gained cytokine functions by accumulating mutations.
2.3. WHEP domain – a third motif originated from tRNA binding
A helix-turn-helix motif named WHEP domain is appended to
ﬁve human tRNA synthetases. These include an N-terminal exten-
H.s. TrpRS
H.s. MetRS
H.s. HisRS
H.s.
GluProRS-R2
Interface I Interface II
MSC p43
H.s. 
TyrRS
I
E
Q
R
S
A24
MD
Y
D R7
E
A
E
A
P
K
K
A
A
L
L
E
E37
EE
K
K K20
K
K
K
V
R
R
N
H.s.
LysRS
H.s.
AspRS
MSC p38
MSC p18
MSC p43
8-2852-79 38-725-32 41-64
H.s. ArgRS
N-terminal single helix
Leucine-zipper motif
EMAPII 
domain
WHEP 
domain
GST domain
Fig. 2. Structures of appended domain/motifs in human AARSs and associated factors. These appended structures provide extra interfaces for protein–protein and protein–
nucleic acid interactions, and are critical for the expanded functions of human AARSs. N-terminal single helices of human AspRS and LysRS are shown to illustrate the
amphiphilic nature of those helices. Clustered negatively- and positively-charged residues are colored in red and blue, respectively. Two protein–protein interaction
interfaces are shown as irregular blue lines on MSC p18 (PDB 2uz8). Conserved residues among WHEP domains in different AARSs are shown as sticks (PDB 1x59, 1r6t, 2djv
for human HisRS, TrpRS and MetRS, respectively, and PDB 1r1b for the second WHEP domain (R2) in GluProRS). The putative cytokine motifs on EMAP II structures of human
TyrRS (PDB 1ntg) and MSC p43 (PDB 1ﬂ0) are shown in yellow. Leucine-zippers appended to ArgRS, MSC p38 and p43 are illustrated.
M. Guo et al. / FEBS Letters 584 (2010) 434–442 437sion added to TrpRS, HisRS and GlyRS, a C-terminal extension on
MetRS, and an insertion that links together the enzymes of the
bifunctional GluProRS. In the latter case, three tandem repeats of
WHEP domains are used to fuse together the two enzymes [59]
(Fig. 1). (The name of WHEP domain comes from 3 of the 5
WHEP-containing proteins: WRS, HRS and EPRS.) Although helix-
turn-helix is a common structural motif, the WHEP domains of
AARSs have sequence similarities that are not found in any non-
AARS. Therefore, the WHEP domain is a true structural invention
for AARSs. It has been introduced into AARSs in metazoans, and
is entirely absent from all AARSs in lower species [60]. Interest-
ingly, removal of the WHEP domain(s) mostly had no effect on
enzymatic activities of the WHEP-containing synthetases [61–64]
suggesting that the role of the WHEP domain is outside of
aminoacylation.
NMR and crystal structure analysis conﬁrmed that WHEP do-
mains have an antiparallel helix-turn-helix conformation, with
consensus lysine and arginine residues forming a basic patch on
one side of the structure [65,66] (Fig. 2). Consistently, the WHEP
domains, either as isolated domain or as tandem repeats such as
those found in GluProRS, are non-speciﬁc RNA-binding domain
[59,65]. Compared with a single WHEP domain, the binding afﬁnity
is largely increased with the three repeated WHEP domains of
GluProRS [65]. In addition to RNA, the WHEP domain repeats of
GluProRS can bind to DNA [59,65]. However, they can also form
protein–protein interactions within the multi-synthetase complex,
with the C-terminal appendix of IleRS, and with the N-terminal
extension of ArgRS [59] (see below).
Remarkably, the three WHEP domain repeats in GluProRS are
essential for the novel role of GluProRS in regulating translation
of speciﬁc genes associated with the inﬂammatory response
(Table 1) [67,68]. The WHEP domains of GluProRS interact withribosomal protein L13a, NS1-associated protein-1 (NSAP1), and
glyceraldehyde-3-phosphate dehydrogenase to form the ‘‘GAIT”
(c-interferon-activated inhibitor of translation) complex. The com-
plex is then brought to the stem–loop structure of the GAIT
element in the 30-UTR of the target mRNAs through WHEP
domain-mediated interactions [69]. Therefore, the WHEP domains
are involved in both protein–protein and protein–RNA interactions
to achieve the novel function of GluProRS in regulating speciﬁc
gene translation.
2.4. GST-like domain – a protein–protein interaction motif
Four class I tRNA synthetases, GluRS (which is linked to ProRS
via 3 WHEP domains), MetRS, ValRS and CysRS, and two of the
three auxiliary factors of the MSC (p38 and p18) contain a glutathi-
one S-transferase (GST)-like domain (Fig. 1). This domain is mostly
absent from lower eukaryote synthetases and is entirely absent in
prokaryotes. GST-like domains, as structural modules, are com-
monly used for protein assembly and to regulate protein folding
[70], and many GST-like domains have no known enzyme activity
(such as those in S-crystallins from squid, eukaryotic elongation
factors 1-c (eEF-1c), 1-b (eEF-1b) and the heat shock protein 26
(HSP26) family of stress-related proteins). Interestingly, GST-like
domains in tRNA synthetases and their target proteins show higher
sequence similarity to each other than to GST-like domains found
elsewhere. Thus, like the WHEP domains, the tRNA synthetase-
associated GST domains have a common origin.
Not surprisingly, all AARSs containing a GST-like domain are
found in complexes with other proteins [5,71]. Human MetRS
and GluProRS are part of the MSC, interacting with MSC p18 and
p38, respectively [30,72]. Mammalian ValRS forms a complex with
eEF-1H (contains a, b, c and d subunits) [28,29,73], and human
438 M. Guo et al. / FEBS Letters 584 (2010) 434–442CysRS binds to eEF-1c [74]. All of these interactions require the
GST-like domains embedded in each AARS.
The crystal structure of the dimeric MSC p18 (composed of a
single GST-like domain) revealed two potential binding surfaces,
including one that resembles the dimeric interface of the GST en-
zyme, and a second binding surface for interacting with another
GST dimer [72] (Fig. 2). Interestingly, to form the primitive yeast
synthetase complex composed of GluRS, MetRS and the yeast aux-
iliary factor Arc1p, the same two interfaces on the GST-like domain
of Arc1p are used to interact with the GST-like domain of GluRS
and of MetRS [71]. Those observations show that the GST-like do-
mains mediate higher-order interactions among AARSs, and the
interactions are conserved from yeast to human. Furthermore,
using one of its two GST binding interfaces, MSC p18 interacts with
ataxia telangiectasia mutated (ATM) (a kinase in response to DNA
damage and oncogenic stress) to act as a tumor suppressor [75,76].
Therefore, as a protein–protein binding motif, the GST-like do-
mains expand the interaction partners of AARSs both inside and
outside of the translational apparatus.
2.5. Leucine-zipper – another protein–protein binding motif
Human ArgRS has a domain-extension that is absent in the
yeast enzyme (Fig. 1). The domain contains two leucine-zipper mo-
tifs, which are also found in MSC p43 and p38 (Fig. 2). The leucine-
zipper is a helical motif that has leucine residues (or other hydro-
phobic residues) at every fourth position of the heptad repeats, so
that the protruding isobutyl side chains are lined up on one side of
the helix. This design creates a hydrophobic spine that inter-locks
with its partner to form a coiled-coil zipper. Signiﬁcantly, leucine-
zipper motifs are widespread, being predicted in 10% of all
eukaryotic proteins that span a wide range of functions [77,78].
All leucine-zipper containing AARSs are components of the MSC
and are associated in the complex, at least in part, through the
leucine-zipper motifs. The leucine-zippers embedded in the N-ter-
minal domain of MSC p43 interact with the amphiphilic leucine-
zipper helix of p38 [30,79,80]. The association of ArgRS into the
MSC is also mediated through its N-terminal leucine-zipper [79].
When the N-terminal leucine-zipper domain of human ArgRS is
absent because of alternative translation initiation, the shorter
form of ArgRS becomes free in cytoplasm, and no longer is associ-
ated with the MSC [10,81,82]. Therefore, leucine-zipper motifs, as
well as the GST-like domains, play a key role in regulating the
binding and release of proteins from the MSC, which thereby acts
as a reservoir for novel functions that get released or silenced on
demand [5,11].
2.6. Other appended domains and sequences
There are other less characterized extensions in human AARSs.
For example, the C-terminal extension of human IleRS contains
two repeats of 90 aa. This extension ﬁrst appears in C. elegans.
These repeats are critical for IleRS to bind to the WHEP domains
of GluProRS in the MSC [83]. A similar C-terminal extension of hu-
man LeuRS also ﬁrst appears in C. elegans. The extension was
shown to have little effect on enzymatic activity [84]. This exten-
sion is involved in binding to the leucine-zipper of ArgRS, and
therefore is important for stabilizing ArgRS and LeuRS in the MSC
[84].
Other appended sequences of human AARS include the N-termi-
nal extension of ThrRS (80 aa), and C-terminal extensions of
SerRS (20 aa) and LysRS (20 residues and not shown in ﬁgures).
These are relatively short and without apparent structures. Inter-
estingly, the C-terminal end of LysRS contains a binding site for
the PDZ domain – a speciﬁc protein–protein interaction motif
found in many proteins involved in signal transduction and intra-cellular trafﬁcking. PDZ domain-containing proteins TIP-15 and
syntenin-1 were found to be associated with LysRS and possibly
also with the MSC [85,86].
In summary, appended domains of human AARS can be sepa-
rated into two groups. The ﬁrst group of appended domains covers
N-terminal amphiphilic helices, and EMAP II and WHEP domains,
all of which appear to be evolved from nucleic acid binding motifs,
but were expanded to interact with protein partners during evolu-
tion. The second group includes GST-like and leucine-zipper motifs
that are protein–protein interaction scaffolds found in many pro-
tein families. These motifs have no known direct nucleic acid bind-
ing interactions. Both groups of domains are involved in the
organization of the MSC, and have been shown to have, or poten-
tially can have, other interactions once the synthetases are re-
leased from the MSC.
3. Functional expansion through adaptation of ancient domains
Apart from functional expansions by directly introducing sepa-
rate domains/motifs into tRNA synthetases, a new function ﬁt for
the need of higher organisms can also be acquired through evolv-
ing pre-existing domains (e.g., the aminoacylation domain and/or
the tRNA anticodon–binding domain). The new function can be
introduced in two different ways. On the one hand, surfaces not
being used for enzymatic functions are obvious candidate sites
for developing new interactions that do not disrupt enzyme activ-
ity. This scenario illustrates the ﬁne structure inventions that had
to occur during evolution. On the other hand, enzymatic functions
and their active sites can be redirected to accommodate new func-
tions. In this case, the active site must be switched from one role to
another, through a speciﬁc structural mechanism.
3.1. New adaptation of unused surface in the catalytic domain
An example of a surface adaptation to acquire a cytokine activ-
ity on the catalytic domain is seen with human TyrRS. A fragment
of human TyrRS – mini-TyrRS – is a product of natural proteolysis.
Mini-TyrRS contains the Rossmann-fold catalytic domain and the
anticodon recognition domains, but lacks the appended EMAP II-
like C-terminal domain. A tripeptide cytokine motif (ELR) that is
critical for the function of interleukin-8 (IL-8)-like cytokines is
embedded in the Rossmann-fold domain of mini-TyrRS. As a result,
mini-TyrRS has ELR motif-dependent cytokine activities [55].
Interestingly, yeast TyrRS lacks the EMAP II-like appended domain
and therefore is an ortholog of human mini-TyrRS [87]. Yeast TyrRS
also lacks the ELR motif and the cytokine activity. When the ELR
motif was grafted into yeast TyrRS at a location corresponding to
its position in human mini-TyrRS, the resulting chimeric protein
had the cytokine activity of the human enzyme [88]. As revealed
in the ultra-high resolution crystal structure of mini-TyrRS
(1.18 Å resolution), the ELR motif is located on an exposed helix
in the Rossmann-fold domain, mostly away from the active site
[89]. Importantly, the ELR motif and the active site of mini-TyrRS
are functionally independent, so that disruption of one site has
no effect on the other [90]. Thus, evolution found a site within
the synthetase to place ELR, without disruption of the essential cat-
alytic activity.
Another example of adapting a surface for new interactions is
seen with human LysRS. The conserved catalytic and anticodon-
binding domains, rather than the appended N-terminal helix motif,
are responsible for binding to p38 in the MSC [30]. Consistent with
the idea that p38 binding does not affect LysRS in aminoacylation,
the p38 binding site on LysRS is separate from the active site and is
not shared for tRNA binding [79]. Interestingly, the p38 binding
site overlaps with the surface containing two eukaryote-speciﬁc
sequences, one in the catalytic domain and another in the
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is created from adaptations to otherwise highly conserved synthe-
tase domains.
Similarly, the association of human GlnRS with MSC is also
through the conserved domains [93], and likely uses a surface
non-essential for aminoacylation.
3.2. Orthogonal use of active site
The most natural way for functional expansion is to utilize what
has already been developed – such as the active site. On this point,
the angiostatic function of TrpRS is active-site dependent. Along
with other angiostatic factors such as interferon-inducible protein
10 (IP-10) and monokine induced by c-interferon (MIG), TrpRS
expression is highly up-regulated by c-interferon (IFN-c) [94,95].
When up-regulated TrpRS is secreted to the extracellular space,
the appended WHEP domain is removed by proteolysis to give
T2-TrpRS – a potent angiostatic factor that acts on endothelial cells
by interacting with a cell–cell junction protein known as vascular
endothelial cadherin (VE-cadherin) [96,97]. The ability of VE-cad-
herin to build junctions depends on two Trp residues near its N-
terminus (Trp2 and Trp4). These protruding side chains bind to a
hydrophobic pocket of a VE-cadherin partner in a neighbor cell,
and vice-versa. Using its tryptophan and AMP binding pockets,
respectively, T2-TrpRS binds to Trp2 and Trp4 of VE-cadherin,
and thereby inhibits the homophilic interaction of VE-cadherins,
breaking up the VE-cadherin-dependent formation of new blood
vessels [98]. Strikingly, if the active site is blocked by the Trp-
AMP adenylate analog, or disrupted by mutagenesis, T2-TrpRS
can no longer inhibit angiogenesis. This example illustrates how
the active site of a tRNA synthetase can be used differently to de-
velop new functions, which can be further regulated by the sub-
strates or the products of the mother synthetase.
3.3. Dimer interface
Many tRNA synthetases require a homodimeric structure for the
aminoacylation function. In those cases, dissociation of the
homodimer would inactivate the enzyme, and simultaneously ex-
pose the dimer interface for potential new interactions. Interest-
ingly, the dimer interface of LysRS is exploited by the Gag
protein of HIV. By interaction with Gag, LysRS is selectively pack-
aged into the HIV-1 virion to facilitate the incorporation of tRNALys,
which is used by the virus as a primer for reverse transcription of
its RNA genome (see above) [37,99]. The LysRS/Gag-CA complex is
a heterodimer [100], and the binding site between LysRS and Gag
has been mapped to the dimerization region of each protein
[101]. As the dimer interface of human LysRS is highly conserved
among LysRSs from different species [92], the interaction appar-
ently was developed through the adaption of the Gag protein of
HIV. However, this example suggests that dimer interface of a tRNA
synthetase is also a possible binding site for host proteins.4. Regulation (activation) of expanded functions
The question of how expanded functions of tRNA synthetases
are regulated is under intense investigation. In the case of human
TyrRS and TrpRS, switching to a new function is controlled by
the removal of an appended domain – the C-terminal EMAP II-like
domain of TyrRS or the N-terminal WHEP domain of TrpRS [102].
In these instances, domain removal, from the full-length native
tRNA synthetase, unmasks the cytokine function. A detailed study
of human TyrRS showed that the EMAP II-like domain shields the
essential ELR motif [89]. Using rational site-directed mutagenesis,
the full-length enzyme was ‘‘opened up” by a single point mutationthat released the tether of the EMAP II-like domain that had
shielded the ELR motif in the native protein. The mutant full-length
enzyme, designated Y341A TyrRS, had the cytokine activity of
mini-TyrRS [103].
In the case of native human TrpRS, the N-terminal WHEP do-
main sterically hinders binding of VE-cadherin, the extracellular
receptor for T2-TrpRS [66,98]. Removal of the WHEP domain, by
alternative splicing or proteolysis, provides access for receptor
binding [104,105]. Thus, for both TyrRS and TrpRS, an appended
domain that appeared only in eukaryotes plays an essential role
in controlling the function. For the bifunctional GluProRS, with
embedded WHEP domains forming the inter-synthetase linker,
the expanded function (of translational repression) is activated
by a phosphorylation event that releases the bifunctional synthe-
tase from the MSC and, thereby, promotes the WHEP-domain-
dependent interactions in the cytoplasm that form the GAIT
complex (see above) [69,106]. These examples, among others
[107], illustrate two different uses of new domains that were
added to eukaryotic tRNA synthetases – as structural elements that
control access to a site needed for an expanded function or as motif
that has a novel interacting partner in eukaryote cell.
5. Concluding remark
Inspection of sequences of human tRNA synthetases predicts
that all AARSs, except for AlaRSs, have expanded domains/motifs
that are not found in their respective orthologs in bacteria or ar-
chaea. We anticipate that all human tRNA synthetases that have
these expansions also have additional functions that are dependent
on, or are regulated by, the introduced domains. In the case of
AlaRS, extreme selective pressure has been exerted through evolu-
tion to develop a framework to prevent serine toxicity from the
misactivation of serine, in addition to the misactivation of glycine
[108–110]. The exceptional evolutionary constraints placed on
AlaRS to ensure its proper function as a synthetase may have lim-
ited the ability of this enzyme to incorporate novel motifs.
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